Non Hodgkin Lymphoma Clinical Trial

Clinical Trial Finder Non Hodgkin Lymphoma Trials

Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies

See Locations Near You

Summary

Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

>18 years old
histologically confirmed solid tumor malignancy
refractory to available therapy or for which no therapy is available
adequate organ function

Exclusion Criteria:

CNS malignancy
significant GI disease
at risk for prolonged QT interval

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

44

Study ID:

NCT00506805

Recruitment Status:

Completed

Sponsor:

Esanex Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Pfizer Investigational Site
Scottsdale Arizona, 85258, United States
Pfizer Investigational Site
Nashville Tennessee, 37203, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

44

Study ID:

NCT00506805

Recruitment Status:

Completed

Sponsor:


Esanex Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Clinical Trials Test State-of-the-Art Cancer Treatments
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider